Sellas Life Sciences Group Inc (NASDAQ: SLS) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced final data from a Phase 2b clinical trial, and the presentation of that data. As you could imagine, the news excited investors who are pushing the stock on a run for the top. Today, we’ll talk about:
- The data;
- what we’re seeing from SLS as a result; and
- what we’ll be watching for with regard to the stock ahead.
SLS Announces Positive Clinical Data
As mentioned above, Sellas Life Sciences is having an incredibly strong start to the trading session this morning after announcing data. In a press release issued early this morning, the company said that data from the prospective, randomized, single-blinded, controlled Phase 2b clinical trial of the combination of nelipepimut +/- trastuzumab was presented at the ESMO 2018 annual meeting.
During the trial, SLS assessed the combination treatment as a possible option for patients with HER2 low-expressing breast cancer. The data proved to be positive with clinically and statistically significant efficacy in tripple negative breast cancer. In fact, the data showed a 75.2% reduction in risk of relapse or death.
The data also showed clinically and statistically significant efficacy in the cohort receiving no hormonal therapy. In this cohort, the treatment led to a 75.9% reduction in risk of relapse or death. Also, the company said that final data at 26 months in patients who have received the combination shows further improvement in clinical benefit versus the interim 19 month data.
In a statement, Dr. Angelos Stergiou, MD, ScD h.c., President and CEO at SLS, had the following to offer:
These data presented at ESMO today highlight the therapeutic potential of NPS for patients with early-stage triple negative breast cancer (TNBC), who currently face limited and ineffective treatment options in the adjuvant setting… The combination of NPS and trastuzumab demonstrated a clinically meaningful and statistically significant difference in the cohort of patients with TNBC with a 75.2% reduction in risk of relapse or death at 26 months. Importantly, following review of the final data that were also assessed by the independent Data Safety Monitoring Board (DSMB) on October 15, 2018, there was an incremental further improvement of clinical benefit to patients now observed in comparison with the data from the interim analysis completed more than six months ago.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. In the case of SLS, the news proved to be overwhelmingly positive. After all, the positive clinical data means that the company is one step closer to regulatory approval for this combination treatment. So, it comes as no surprise that excited investors are sending the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:46), SLS is trading at $1.74 per share after a gain of $0.18 per share or 11.54% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on SLS. In particular, we’re interested in following the story surrounding the company’s continued work to bring this combination treatment as well as the rest of its clinical stage pipeline to market. Nonetheless, we’ll continue to keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!